Section Arrow
TIL.NASDAQ
- Instil Bio
Quotes are at least 15-min delayed:2025/11/22 20:38 EST
Regular Hours
Last
 13.14
+1.17 (+9.77%)
Day High 
13.5 
Prev. Close
11.97 
1-M High
20.315 
Volume 
130.08K 
Bid
11.52
Ask
12.25
Day Low
11.56 
Open
12.15 
1-M Low
11.82 
Market Cap 
81.18M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.89 
20-SMA 15.57 
50-SMA 18.01 
52-W High 42.79 
52-W Low 10.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.91/-8.81
Enterprise Value
166.38M
Balance Sheet
Book Value Per Share
17.76
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OSRHOSR Holdings Inc.0.5626+0.1066+23.38%-- 
SGMOSangamo Therapeutics0.4234+0.0384+9.97%-- 
RXRXRecursion Pharmaceuticals4.17+0.32+8.31%-- 
CYPHCypherpunk Technologies Inc.2.28-0.66-22.45%-- 
ASBPAspire Biopharma Holdings Inc.0.0974-0.0003-0.31%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.